Top Story

CTL019 therapy induced sustained remission in relapsed, refractory ALL

October 30, 2014

PHILADELPHIA — David L. Porter, MD, director of blood and marrow transplantation at Abramson Cancer Center at the University of Pennsylvania, discusses study results that showed chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and refractory acute lymphoblastic leukemia.

The patients who participated in these trials had relapsed as many as four times, and 60% had their cancers return following bone marrow or stem cell transplants.

Worth Building

Question your allocation to deal with recent stock market volatility

October 30, 2014
The summer stock market doldrums have morphed into a high octane volatile zig-zag. So I ask you – what is new? Haven’t we been here before? The trouble is…
Meeting News Coverage

Gender, lymph node ratio linked to papillary thyroid carcinoma recurrence

October 30, 2014
CORONADO, Calif. — Elevated lymph node ratio and male gender were strongly associated with poorer disease-free survival among patients with papillary thyroid…
FDA News

FDA approves clinical trial for potential HCC chemotherapy drug

October 30, 2014
The FDA approved the initiation of an investigational device exemption clinical trial of a potential chemotherapy drug, Oncozene, for the treatment of hepatocellular…
More News Headlines »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Video
figure

CTL019 therapy induced sustained remission in relapsed, refractory ALL

October 30, 2014
PHILADELPHIA — David L. Porter, MD, director of blood and marrow transplantation at Abramson Cancer Center at…
More »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »